nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—ELMO1—esophageal cancer	0.0447	0.0514	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—CFL1—esophageal cancer	0.0403	0.0463	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cross-presentation of soluble exogenous antigens (endosomes)—PSME1—esophageal cancer	0.0359	0.0413	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cross-presentation of soluble exogenous antigens (endosomes)—PSME2—esophageal cancer	0.0359	0.0413	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—ACTB—esophageal cancer	0.0343	0.0394	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—ELMO1—esophageal cancer	0.0337	0.0388	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—CFL1—esophageal cancer	0.0304	0.035	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—RNF6—esophageal cancer	0.0293	0.0337	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—PTPN2—esophageal cancer	0.0287	0.033	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—B2M—esophageal cancer	0.0284	0.0327	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—ACTB—esophageal cancer	0.0259	0.0298	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—B2M—esophageal cancer	0.0252	0.029	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—PSME2—esophageal cancer	0.0238	0.0274	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—PSME1—esophageal cancer	0.0238	0.0274	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—ABL1—esophageal cancer	0.0229	0.0264	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—CALR—esophageal cancer	0.0229	0.0263	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—MAP3K3—esophageal cancer	0.0178	0.0205	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—ABL1—esophageal cancer	0.0173	0.0199	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CAPZA1—esophageal cancer	0.0151	0.0174	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—RNF6—esophageal cancer	0.0145	0.0167	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—PIK3CA—esophageal cancer	0.0145	0.0166	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—PTPN2—esophageal cancer	0.014	0.0161	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—B2M—esophageal cancer	0.0139	0.016	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TMEM173—esophageal cancer	0.0119	0.0137	CbGpPWpGaD
Methyl aminolevulinate—Localized exfoliation—Capecitabine—esophageal cancer	0.0107	0.082	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—B2M—esophageal cancer	0.0101	0.0116	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—PSME2—esophageal cancer	0.00952	0.0109	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—PSME1—esophageal cancer	0.00952	0.0109	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—HSPA5—esophageal cancer	0.00943	0.0108	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PTPN2—esophageal cancer	0.00937	0.0108	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—B2M—esophageal cancer	0.00926	0.0107	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—CALR—esophageal cancer	0.00914	0.0105	CbGpPWpGaD
Methyl aminolevulinate—Scab—Capecitabine—esophageal cancer	0.00905	0.0694	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—FBXW7—esophageal cancer	0.00884	0.0102	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—RNF6—esophageal cancer	0.00879	0.0101	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CAPZA1—esophageal cancer	0.00879	0.0101	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CTSC—esophageal cancer	0.00817	0.00939	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ELMO1—esophageal cancer	0.00701	0.00806	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TMEM173—esophageal cancer	0.00695	0.00799	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CFL1—esophageal cancer	0.00633	0.00727	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—LGALS3—esophageal cancer	0.00606	0.00697	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MAP3K3—esophageal cancer	0.00583	0.0067	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—PIK3CA—esophageal cancer	0.00565	0.00649	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ACTB—esophageal cancer	0.00538	0.00619	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—B2M—esophageal cancer	0.0052	0.00597	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—B2M—esophageal cancer	0.00499	0.00574	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CTSC—esophageal cancer	0.00495	0.0057	CbGpPWpGaD
Methyl aminolevulinate—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.00484	0.0371	CcSEcCtD
Methyl aminolevulinate—Infection—Carboplatin—esophageal cancer	0.00472	0.0362	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PSME1—esophageal cancer	0.00471	0.00542	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PSME2—esophageal cancer	0.00471	0.00542	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HSPA5—esophageal cancer	0.00467	0.00537	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CALR—esophageal cancer	0.00452	0.0052	CbGpPWpGaD
Methyl aminolevulinate—Keratitis—Capecitabine—esophageal cancer	0.00444	0.034	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FBXW7—esophageal cancer	0.00437	0.00503	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HMGB1—esophageal cancer	0.00435	0.00501	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Cisplatin—esophageal cancer	0.00413	0.0317	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ELMO1—esophageal cancer	0.00408	0.0047	CbGpPWpGaD
Methyl aminolevulinate—Pain—Carboplatin—esophageal cancer	0.00406	0.0312	CcSEcCtD
Methyl aminolevulinate—Blister—Capecitabine—esophageal cancer	0.00399	0.0306	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Cisplatin—esophageal cancer	0.00373	0.0286	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Capecitabine—esophageal cancer	0.0037	0.0284	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CFL1—esophageal cancer	0.00368	0.00424	CbGpPWpGaD
Methyl aminolevulinate—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.0036	0.0276	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ABL1—esophageal cancer	0.0036	0.00414	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—LGALS3—esophageal cancer	0.00353	0.00406	CbGpPWpGaD
Methyl aminolevulinate—Eye irritation—Capecitabine—esophageal cancer	0.00337	0.0259	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ACTB—esophageal cancer	0.00313	0.0036	CbGpPWpGaD
Methyl aminolevulinate—Burning sensation—Methotrexate—esophageal cancer	0.00308	0.0237	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PTPN2—esophageal cancer	0.00306	0.00352	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Capecitabine—esophageal cancer	0.00304	0.0233	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—B2M—esophageal cancer	0.00303	0.00348	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PSME1—esophageal cancer	0.00286	0.00329	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PSME2—esophageal cancer	0.00286	0.00329	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—HSPA5—esophageal cancer	0.00283	0.00326	CbGpPWpGaD
Methyl aminolevulinate—Skin ulcer—Methotrexate—esophageal cancer	0.00275	0.0211	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Capecitabine—esophageal cancer	0.00275	0.0211	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CALR—esophageal cancer	0.00274	0.00315	CbGpPWpGaD
Methyl aminolevulinate—Face oedema—Cisplatin—esophageal cancer	0.00274	0.021	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TLR4—esophageal cancer	0.00273	0.00314	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—FBXW7—esophageal cancer	0.00265	0.00305	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—HMGB1—esophageal cancer	0.00254	0.00292	CbGpPWpGaD
Methyl aminolevulinate—Swelling—Capecitabine—esophageal cancer	0.00237	0.0182	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CASP8—esophageal cancer	0.00234	0.00269	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CREBBP—esophageal cancer	0.00233	0.00268	CbGpPWpGaD
Methyl aminolevulinate—Eye pain—Capecitabine—esophageal cancer	0.00231	0.0178	CcSEcCtD
Methyl aminolevulinate—Ulcer—Methotrexate—esophageal cancer	0.00226	0.0174	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Capecitabine—esophageal cancer	0.00219	0.0168	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ABL1—esophageal cancer	0.0021	0.00241	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PIK3CA—esophageal cancer	0.00209	0.00241	CbGpPWpGaD
Methyl aminolevulinate—Skin exfoliation—Methotrexate—esophageal cancer	0.00205	0.0157	CcSEcCtD
Methyl aminolevulinate—Face oedema—Capecitabine—esophageal cancer	0.00202	0.0155	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—BCL2—esophageal cancer	0.00201	0.00231	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ERBB2—esophageal cancer	0.00195	0.00224	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ERBB2—esophageal cancer	0.00187	0.00216	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Cisplatin—esophageal cancer	0.00183	0.0141	CcSEcCtD
Methyl aminolevulinate—Erythema—Cisplatin—esophageal cancer	0.00171	0.0131	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CDKN1A—esophageal cancer	0.00167	0.00192	CbGpPWpGaD
Methyl aminolevulinate—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00165	0.0126	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDKN1A—esophageal cancer	0.0016	0.00184	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TLR4—esophageal cancer	0.00159	0.00183	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EP300—esophageal cancer	0.00159	0.00183	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Cisplatin—esophageal cancer	0.00144	0.011	CcSEcCtD
Methyl aminolevulinate—Oedema—Cisplatin—esophageal cancer	0.00139	0.0107	CcSEcCtD
Methyl aminolevulinate—Infection—Cisplatin—esophageal cancer	0.00138	0.0106	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CASP8—esophageal cancer	0.00136	0.00157	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CREBBP—esophageal cancer	0.00136	0.00156	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EGFR—esophageal cancer	0.00135	0.00156	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Capecitabine—esophageal cancer	0.00135	0.0104	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—EGFR—esophageal cancer	0.0013	0.00149	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Capecitabine—esophageal cancer	0.00126	0.00965	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Cisplatin—esophageal cancer	0.00125	0.0096	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00123	0.00941	CcSEcCtD
Methyl aminolevulinate—Pain—Cisplatin—esophageal cancer	0.00119	0.00914	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PIK3CA—esophageal cancer	0.00117	0.00135	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BCL2—esophageal cancer	0.00117	0.00135	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—ERBB2—esophageal cancer	0.00114	0.00131	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PIK3CA—esophageal cancer	0.00113	0.0013	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Capecitabine—esophageal cancer	0.00106	0.00812	CcSEcCtD
Methyl aminolevulinate—Oedema—Capecitabine—esophageal cancer	0.00103	0.00788	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Cisplatin—esophageal cancer	0.00103	0.00787	CcSEcCtD
Methyl aminolevulinate—Infection—Capecitabine—esophageal cancer	0.00102	0.00783	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Methotrexate—esophageal cancer	0.00101	0.00771	CcSEcCtD
Methyl aminolevulinate—Asthenia—Cisplatin—esophageal cancer	0.000999	0.00767	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CDKN1A—esophageal cancer	0.000972	0.00112	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Methotrexate—esophageal cancer	0.000937	0.00719	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—EP300—esophageal cancer	0.000925	0.00106	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Capecitabine—esophageal cancer	0.000922	0.00707	CcSEcCtD
Methyl aminolevulinate—Fatigue—Capecitabine—esophageal cancer	0.000885	0.00679	CcSEcCtD
Methyl aminolevulinate—Rash—Cisplatin—esophageal cancer	0.000878	0.00674	CcSEcCtD
Methyl aminolevulinate—Pain—Capecitabine—esophageal cancer	0.000878	0.00674	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Cisplatin—esophageal cancer	0.000877	0.00673	CcSEcCtD
Methyl aminolevulinate—Nausea—Cisplatin—esophageal cancer	0.000827	0.00635	CcSEcCtD
Methyl aminolevulinate—Urticaria—Capecitabine—esophageal cancer	0.000816	0.00626	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—EGFR—esophageal cancer	0.000788	0.000906	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Methotrexate—esophageal cancer	0.000788	0.00604	CcSEcCtD
Methyl aminolevulinate—Infection—Methotrexate—esophageal cancer	0.000759	0.00583	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Capecitabine—esophageal cancer	0.000756	0.0058	CcSEcCtD
Methyl aminolevulinate—Asthenia—Capecitabine—esophageal cancer	0.000737	0.00565	CcSEcCtD
Methyl aminolevulinate—Pruritus—Capecitabine—esophageal cancer	0.000726	0.00557	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Methotrexate—esophageal cancer	0.000686	0.00527	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PIK3CA—esophageal cancer	0.000684	0.000786	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Capecitabine—esophageal cancer	0.000679	0.00521	CcSEcCtD
Methyl aminolevulinate—Fatigue—Methotrexate—esophageal cancer	0.000659	0.00506	CcSEcCtD
Methyl aminolevulinate—Pain—Methotrexate—esophageal cancer	0.000654	0.00501	CcSEcCtD
Methyl aminolevulinate—Rash—Capecitabine—esophageal cancer	0.000647	0.00497	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Capecitabine—esophageal cancer	0.000647	0.00496	CcSEcCtD
Methyl aminolevulinate—Headache—Capecitabine—esophageal cancer	0.000643	0.00494	CcSEcCtD
Methyl aminolevulinate—Nausea—Capecitabine—esophageal cancer	0.00061	0.00468	CcSEcCtD
Methyl aminolevulinate—Urticaria—Methotrexate—esophageal cancer	0.000607	0.00466	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Methotrexate—esophageal cancer	0.000563	0.00432	CcSEcCtD
Methyl aminolevulinate—Asthenia—Methotrexate—esophageal cancer	0.000548	0.00421	CcSEcCtD
Methyl aminolevulinate—Pruritus—Methotrexate—esophageal cancer	0.000541	0.00415	CcSEcCtD
Methyl aminolevulinate—Dizziness—Methotrexate—esophageal cancer	0.000505	0.00388	CcSEcCtD
Methyl aminolevulinate—Rash—Methotrexate—esophageal cancer	0.000482	0.0037	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Methotrexate—esophageal cancer	0.000481	0.00369	CcSEcCtD
Methyl aminolevulinate—Headache—Methotrexate—esophageal cancer	0.000479	0.00367	CcSEcCtD
Methyl aminolevulinate—Nausea—Methotrexate—esophageal cancer	0.000454	0.00348	CcSEcCtD
